ImmuPharma's lupus candidate misses in Phase III

ImmuPharma plc (LSE:IMM) said lead product Lupuzor (forigerimod, P140) missed the primary endpoint in a Phase III trial to treat systemic lupus erythematosus (SLE). The company said it will review the trial's full data set and work with its regulatory advisers to determine next steps.

On the 202-patient trial's primary endpoint, 200 μg subcutaneous Lupuzor every four weeks plus standard of care (SOC) for 48 weeks failed to significantly improve the proportion of patients who achieved an SLE Responder Index (SRI)-4 response at week 52 vs. placebo plus SOC (52.5% vs. 44.6%, p=0.2631). ImmuPharma said the endpoint was missed due to a high placebo response rate...